Competing Breast Cancer Assays Beat Genomic Health's Oncotype Dx in Canadian Cost Modeling Study
Genomeweb,
NEW YORK – A cost effectiveness analysis published last month by a team of Canadian authors has added another factor to the…
NEW YORK – A cost effectiveness analysis published last month by a team of Canadian authors has added another factor to the…
Findings Show EndoPredict Was Significantly More Cost Effective than Oncotype DX™ SALT LAKE CITY, June 25, 2019 (GLOBE NEWSWIRE…
Findings Show EndoPredict Was Significantly More Cost Effective than Oncotype DX™ SALT LAKE CITY, June 25, 2019 (GLOBE NEWSWIRE…
(GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that The…
(GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, today announced that The…
( ) SALT LAKE CITY, June 25, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized…
– Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that The Pharmacogenomics…
SALT LAKE CITY, June 25, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine…
Related Biotechnology, Pharmaceutical and Healthcare News Original Article: Cost-effectiveness analysis of multigene expression…